Hydroxy Acetildenafil (CAS 147676-56-0)

Hydroxy Acetildenafil, a structural analogue of Sildenafil, is primarily recognized for its role in research related to the study of phosphodiesterase type 5 (PDE5) inhibitors. This compound, by mimicking the action of Sildenafil, aids in elucidating the biochemical pathways involved in the regulation of cyclic guanosine monophosphate (cGMP) within cellular environments. The mechanism of action revolves around its ability to competitively inhibit the PDE5 enzyme, which is responsible for the degradation of cGMP. cGMP serves as a secondary messenger within various biochemical pathways, particularly those involved in signal transduction processes. By preventing the breakdown of cGMP, Hydroxy Acetildenafil facilitates the accumulation of this molecule, thereby providing a model to study the effects of enhanced cGMP levels within cells. This is particularly valuable in research focusing on the molecular basis of cellular responses to different stimuli and the exploration of potential therapeutic targets for diseases characterized by dysregulated cGMP signaling pathways.